KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Debt to Equity (2016 - 2025)

Sarepta Therapeutics has reported Debt to Equity over the past 15 years, most recently at $0.73 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.73 for Q4 2025, down 2.36% from a year ago — trailing twelve months through Dec 2025 was $0.73 (down 2.36% YoY), and the annual figure for FY2025 was $0.73, down 2.36%.
  • Debt to Equity for Q4 2025 was $0.73 at Sarepta Therapeutics, down from $0.81 in the prior quarter.
  • Over the last five years, Debt to Equity for SRPT hit a ceiling of $4.01 in Q4 2022 and a floor of $0.73 in Q4 2025.
  • Median Debt to Equity over the past 5 years was $1.36 (2023), compared with a mean of $1.61.
  • Biggest five-year swings in Debt to Equity: surged 239.41% in 2022 and later plummeted 64.09% in 2023.
  • Sarepta Therapeutics' Debt to Equity stood at $1.18 in 2021, then surged by 239.41% to $4.01 in 2022, then plummeted by 64.09% to $1.44 in 2023, then tumbled by 48.33% to $0.74 in 2024, then dropped by 2.36% to $0.73 in 2025.
  • The last three reported values for Debt to Equity were $0.73 (Q4 2025), $0.81 (Q3 2025), and $0.84 (Q2 2025) per Business Quant data.